[Salozinal in the treatment of the irritable bowel syndrome in young persons].
OBJECTIVE
To ascertain whether salozinal improves short- and long-term treatment outcomes in young patients.


METHODS
Salozinal was given in a daily dose 4-6 g to 32 patients depending on the length of the colon lesion. All the patients were subjected to colonofibroscopy with obligatory spot biopsy and morphological examination, evaluation of lipid peroxidation (LPO), antioxidant defense (AOD) and immunological indices.


RESULTS
The endoscopic picture improved in 27, histologic one in 26, stool in 28 patients. Negative results were absent. A positive trend was observed in LPO and AOD.


CONCLUSIONS
A high response rate to salozinal in young patients with irritable colon syndrome is achieved, among other mechanisms, through block of the cyclooxigenase pathway indirectly confirmed by normalization of LPO and AOD.
Preobrazhenskiĭ
V N
VN
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000917:Antibody Formation / Q000187:drug effects; D001706:Biopsy; D003106:Colon / Q000378:metabolism / Q000473:pathology; D003109:Colonic Diseases, Functional / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D003113:Colonoscopy; D005336:Fiber Optic Technology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D015227:Lipid Peroxidation / Q000187:drug effects; D019804:Mesalamine / Q000627:therapeutic use*; D012460:Sulfasalazine / Q000627:therapeutic use; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D012460:Sulfasalazine; D019804:Mesalamine